Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial

Fig. 2

Potential mechanisms implicated in empagliflozin’s beneficial effects on the myocardium (on the left) and the biohuoral/instrumental tests performed to highlight them (on the right of the figure). The red vertical arrows indicate an increment, the blue vertical ones indicate a decrement. cyt cytoplasm, GLS global longitudinal strain, hsCRP high-sensitive C-reactive protein, KB ketone bodies, m mitochondrion, TBW total body water, TNF-α tumor necrosis factor-alpha, VO 2 max O2 consuption at peak of stress

Back to article page